DFCI @ Foxborough

Foxborough, Massachusetts 02035

1 studies enrolling now · 3 studies all time

What they study most

Breast Cancer, HER2-negative Breast Cancer, HER2-positive Breast Cancer, HR-Positive Breast Cancer, Invasive Breast Cancer, Metastatic Breast Cancer, PD-L1 Negative, Triple Negative Breast Cancer

Studies at this site

• Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC — Recruiting now
• STOP-HER2: Stopping Trastuzumab in HER2+ MBC — Running, not enrolling
• Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC — Running, not enrolling